Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided deferred adjuvant therapy in resectable early-stage colon cancer
ChiCTR2300072958Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, oxaliplatin, irinotecan, folinic acid and fluorouracil in colon adenocarcinoma (4 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Overall survival in MRD-negative groups, Overall survival in MRD-positive groups and 2 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
capecitabineoxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300072958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072958.